Alternative Name
KRAS Liquid Biopsy Testing
Methodology
Molecular
Test Description

Bi-directional sequencing of exons 2 and 3 of the KRAS gene. High-sensitivity sequencing is used for enhanced detection of mutations in codons 12, 13, 59, and 61. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity. Note - NeoLAB™ KRAS Mutation Analysis- Liquid Biopsy will only be performed for hematological diseases at this time.

Clinical Significance

Testing is recommended as a follow-up in patients with AML or MDS/CMML with confirmed KRAS mutations. In addition, this test can be used for screening and determining if a bone marrow biopsy is an absolute necessity, as well as monitoring disease status. It can also be used for performing molecular studies when a bone marrow sample is inadequate (dry tap, insufficient quantity, or not viable), or not available. This test should not be used for solid tumors. Tissue-based testing is recommended for solid tumors.

Specimen Requirements

Peripheral blood: 2 x 6 mL EDTA tubes (total 12 mL)or 10 mL in EDTA tube.

Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <72 hours old preferred.

CPT Code(s)*
81275, 81276
Medicare MolDX CPT Code(s)*
81479
Turnaround Time

7 days

Level of Service
Global

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.